Incyte Corporation is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics, primarily targeting oncology and inflammation. The company's lead product, JAKAFI, is approved for treating myelofibrosis and polycythemia vera, while Iclusig is used for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Incyte is advancing several clinical-stage programs, including treatments for chronic graft-versus-host disease, essential thrombocythemia, and advanced cancers like bladder cancer and follicular lymphoma. The company has also launched dermatology products, such as Opzelura, which is approved for atopic dermatitis and vitiligo. Incyte actively collaborates with various pharmaceutical companies to enhance the development and commercialization of its product pipeline, which is designed to address unmet medical needs. Founded in 1991 and headquartered in Wilmington, Delaware, Incyte aims to deliver innovative therapies to patients worldwide.
Escient Pharmaceuticals is a biotechnology company based in San Diego, California, that develops and manufactures drugs targeting G protein-coupled receptors (GPCRs) for the treatment of neuro-immuno-inflammatory and autoreactive diseases. Founded in 2017, the company specializes in harnessing the therapeutic potential of specific orphan GPCRs, particularly the Mas-Related G-Protein Receptors (Mrgprs), to address various neurosensory-inflammatory disorders. Escient's innovative approach aims to provide first-in-class therapies for conditions associated with mast cell-mediated disorders and cholestatic pruritus, thereby expanding treatment options for healthcare providers and patients facing these challenging diseases.
BioTheryx
Corporate Round in 2023
BioTheryX, Inc. is a clinical-stage biopharmaceutical company based in Chappaqua, New York, focused on developing innovative therapies that restore protein homeostasis through targeted protein degradation. The company specializes in Protein Homeostatic Modulators and small molecule targeted protein degraders (TPDs), which utilize a unique mechanism involving molecular glues to regulate protein levels within the body. Their proprietary PRODEGY platform is built on a library of Cereblon binders, enabling the design of bifunctional and hybrid degraders aimed at treating various diseases, particularly cancer. BioTheryX's lead candidate, BTX-A51, is an oral small molecule and multi-kinase inhibitor targeting specific leukemic stem cells and oncogenic transcription factors. Established in 2007, BioTheryX aims to address significant unmet medical needs by leveraging its expertise in protein modulation and degradation.
Villaris Therapeutics
Acquisition in 2022
Villaris Therapeutics is focused on developing innovative humanized antibody therapeutics aimed at treating vitiligo, a condition that affects skin pigmentation. The company's approach involves targeting and depleting autoimmune memory T cells, which play a role in the disease's pathology. By specifically addressing the immune response that attacks pigmentation cells, Villaris Therapeutics aims to provide an effective and durable treatment option for vitiligo and potentially other tissue-specific autoimmune diseases that involve similar mechanisms. This novel therapeutic strategy seeks to improve the quality of life for individuals living with vitiligo through advancements in biomedical research.
Agenus
Post in 2017
Agenus Inc. is a clinical-stage immuno-oncology company focused on the discovery, development, and commercialization of innovative immunotherapies and vaccines for cancer and infectious diseases. Based in Lexington, Massachusetts, the company aims to activate the immune system to recognize and combat cancer cells through a diverse portfolio that includes checkpoint antibodies, tumor microenvironment modifiers, and vaccine adjuvants. Agenus utilizes its proprietary Retrocyte Display platform for antibody discovery and develops a range of therapeutic candidates, including monoclonal antibodies and vaccines targeting various tumor-specific neo-epitopes. The company has several products in clinical trials, including CTLA-4 and PD-1 antagonists, and collaborates with notable partners such as Incyte Corporation and Merck Sharpe & Dohme to advance its immuno-oncology therapies. Founded in 1994, Agenus continues to build its capabilities in research, development, and manufacturing within the field of immunotherapy.
ARIAD Pharmaceuticals - European operations
Acquisition in 2016
ARIAD Pharmaceuticals - European operations focuses on cancer.
Maxia Pharmaceuticals
Acquisition in 2003
Maxia Pharmaceuticals is a privately-held drug discovery and development company that specialized in small molecule drugs.
Iconix Biosciences
Venture Round in 2002
Iconix Biosciences focuses on toxicogenomics by providing a comprehensive database known as DrugMatrix®, which includes microarray and pharmacology data. The company possesses the expertise to analyze and interpret this extensive information, enabling researchers to gain insights into drug toxicity. Additionally, Iconix has developed Drug Signatures®, a collection of genomic biomarkers that predict specific toxicological outcomes and mechanisms of action. This capability supports pharmaceutical research and development by identifying potential risks associated with drug compounds.
De Novo Pharmaceuticals
Series B in 2001
De Novo Pharmaceuticals is an emerging computational drug design company. De Novo Pharmaceuticals uses its proprietary computational software for drug design to create novel, patentable lead molecules as candidates for drug development. De Novo's proprietary algorithms can convert information from structural genomics and medicinal chemistry rapidly into new chemical designs, maximising value within a pharmaceutical partner's research portfolio. De Novo's drug discovery partners include British Biotechnology, Aventis Pharmaceuticals and NV Organon.
Proteome
Acquisition in 2000
Proteome is a privately held company specializing in proteomics information. It has created an integrated biological knowledge system that supports researchers by providing essential insights into gene and protein function. The company's BioKnowledge Library serves as a comprehensive database of annotations for over 50,000 proteins across various organisms, including humans, rats, mice, worms, and yeast. This extensive database is curated by a network of nearly 100 scientists and includes tools that convert scientific publications into analyzable relational data. These capabilities enable scientists to perform online searches for advanced protein analysis, facilitating deeper understanding and exploration in the field of proteomics.
GeneEd
Seed Round in 2000
GeneEd is the leading provider of e-Learning solutions for life science, combining advanced web technologies, creative design and educational skills into a productive and compelling learning experience. They take validated content created by domain experts and transform it into accredited multimedia courses including animations with synchronized streaming audio and thoughtfully designed interactive exercises. The courses are viewed in their Webinar™ environment that captures all of the positive attributes of a live seminar but retains the "anytime, any place, any pace" power of the internet. Their catalog courses are delivered using a platform that allows online registration, as well as student testing and tracking for corporate clients.
Synteni
Acquisition in 1998
Synteni is a privately held microarray-based gene expression company. The company specializes in genetic research.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.